Skip to content

US · IRMD · MEDICAL - DEVICES

IRadimed Corporation (IRMD) intrinsic value and stock valuation

$81.02as of 2026-11-21 · Mkt cap 1.17B

Data updated · price as of 2026-11-21

OvervaluedIC value is 20–50% below the price. The exact IC value, upside and the fair-value band are available with Pro.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

IRadimed Corporation DCF and intrinsic value

InvestorsCraft values IRMD with the Chepakovich two-stage DCF model — currently rated overvalued. How the model works · Run your own DCF prefilled from IRMD’s statements →

IRadimed Corporation Graham Number

Graham Number: $17.20d — the price is above the Graham Number. Formula √(22.5 × EPS × BVPS) using the latest diluted EPS and book value per share. Guide · Calculator →

Healthcare · Medical - Devices Orlando, FL 32826 iradimed.com

How the business is doing

Fiscal 2012–2025, USD

Revenue
$83.8M+21.4% 5y CAGRd
20122025
Net income
$22.5M+75% 5y CAGRd
20122025
Free cash flow
$17.2M+27.1% 5y CAGRd
20122025
Total equity
$94.6M+9% 5y CAGRd
20122025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2012–2025, USD
20252024202320222021
Revenue$83.8M$73.2M$65.6M$53.3M$41.8M
Operating income$26.2M$22M$20M$15.6M$9.82M
Net income$22.5M$19.2M$17.2M$12.8M$9.33M
EPSd$1.75M$1.5M$1.35M$1.02M$741.1K
Operating cash flow$25M$25.6M$13.5M$10M$11.3M
Capital expenditure-$-7.76M-$-8.01M-$-8.01M-$-1.87M-$-740K
Free cash flow$17.2M$17.6M$5.46M$8.17M$10.5M
Total assets$108.8M$98.3M$92.2M$85.5M$82.9M
Total debt$0.00$150K$2.04M$2.21M$2.48M
Net debt-$-51.16M-$-52.08M-$-47.72M-$-55.76M-$-59.52M
Total equity$94.6M$86.8M$71.4M$73.7M$72.2M
Cash and short-term investments$51.2M$52.2M$49.8M$58M$62.5M
Income statement
20252024202320222021
Revenue$83.8M$73.2M$65.6M$53.3M$41.8M
Cost of revenue$19.5M$16.9M$15.4M$12M$9.76M
Gross profit$64.3M$56.4M$50.2M$41.3M$32.1M
Research and development expenses$2.98M$2.83M$2.86M$2.28M$1.91M
Selling, general and administrative expenses$35.2M$31.6M$27.3M$23.4M$20.3M
Other expenses$0.00$0.00$0.00$0.00$0.00
Operating expenses$38.2M$34.4M$30.1M$25.7M$22.2M
Cost and expenses$57.7M$51.3M$45.5M$37.7M$32M
Interest income$0.00$2.19M$1.86M$580K$30K
Interest expense$0.00$0.00$0.00$0.00$0.00
Depreciation and amortization$2.38M$820K$770K$670K$1.41M
Ebitda$30.7M$25.1M$22.5M$16.9M$11.2M
Operating income$26.2M$22M$20M$15.6M$9.82M
Total other income/expenses, net$2.21M$2.31M$1.7M$550K$20K
Income before tax$28.4M$24.3M$21.7M$16.2M$9.84M
Income tax expense$5.88M$5.04M$4.55M$3.35M$510K
Net income$22.5M$19.2M$17.2M$12.8M$9.33M
Weighted average shares outstanding$12.7M$12.7M$12.6M$12.6M$12.4M
Weighted average diluted shares outstanding$12.9M$12.8M$12.7M$12.6M$12.6M
Balance sheet
20252024202320222021
Cash and short-term investments$51.2M$52.2M$49.8M$58M$62.5M
Net receivables$13.7M$10.6M$12.2M$13.3M$5.14M
Inventory$11.6M$10.4M$12.8M$5.37M$4.3M
Total current assets$81.2M$75.2M$76M$77.5M$76.2M
Property, plant and equipment, net$23.9M$17M$11.3M$4.61M$4.55M
Goodwill and intangible assets$3.38M$3.1M$2.52M$2.07M$1.12M
Long-term investments$0.00$0.00$0.00$0.00$0.00
Total non-current assets$27.6M$23.1M$16.2M$8.02M$6.64M
Total assets$108.8M$98.3M$92.2M$85.5M$82.9M
Accounts payable$1.82M$1.9M$1.86M$1.8M$780K
Short-term debt$0.00$150K$430K$290K$280K
Deferred revenue$2.87M$2.26M$2.57M$3.37M$2.55M
Total current liabilities$10.2M$8.51M$16.3M$8.55M$6.82M
Long-term debt$0.00$0.00$1.62M$1.91M$2.21M
Deferred revenue, non-current$3.98M$2.99M$2.79M$1.38M$1.68M
Total non-current liabilities$3.98M$2.99M$4.41M$3.29M$3.88M
Capital lease obligations$0.00$150K$2.04M$2.21M$2.48M
Total liabilities$14.2M$11.5M$20.7M$11.8M$10.7M
Common stock$0.00$0.00$0.00$0.00$0.00
Retained earnings$64.2M$56.8M$43.3M$47.3M$47M
Accumulated other comprehensive income (loss)$0.00$0.00$0.00$0.00$20K
Total equity$94.6M$86.8M$71.4M$73.7M$72.2M
Total investments$0.00$0.00$0.00$0.00$500K
Total debt$0.00$150K$2.04M$2.21M$2.48M
Net debt-$-51.16M-$-52.08M-$-47.72M-$-55.76M-$-59.52M
Cash flow statement
20252024202320222021
Net income$22.5M$19.2M$17.2M$12.8M$9.33M
Depreciation and amortization$1.17M$820K$770K$670K$1.41M
Stock-based compensation$2.92M$2.52M$2.19M$1.39M$1.46M
Change in working capital-$-4.34M$3.75M-$-5.91M-$-5.06M-$-1.58M
Accounts receivable-$-3.03M$1.76M$840K-$-8.24M-$-580K
Inventory-$-1.38M$3.13M-$-7.47M-$-1.31M-$-390K
Accounts payable-$-80K-$-860K-$-220K$1.12M$30K
Net cash provided by operating activities$25M$25.6M$13.5M$10M$11.3M
Investments in property, plant and equipment-$-7.76M-$-8.01M-$-7.44M-$-820K-$-480K
Acquisitions, net$0.00$0.00$0.00$0.00$0.00
Net cash used for investing activities-$-8.42M-$-8.82M-$-8.01M-$-1.37M$650K
Common stock issued$0.00$30K$0.00$0.00$0.00
Common stock repurchased$0.00$0.00$0.00$0.00$0.00
Dividends paid-$-15.04M-$-13.68M-$-13.22M-$-12.56M$0.00
Net cash used for financing activities-$-17.6M-$-14.34M-$-13.66M-$-12.71M$20K
Net change in cash-$-1.07M$2.47M-$-8.2M-$-4.04M$11.9M
Cash at end of period$51.2M$52.2M$49.8M$58M$62M
Operating cash flow$25M$25.6M$13.5M$10M$11.3M
Capital expenditure-$-7.76M-$-8.01M-$-8.01M-$-1.87M-$-740K
Free cash flow$17.2M$17.6M$5.46M$8.17M$10.5M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About IRadimed Corporation

        IRADIMED CORPORATION specializes in the engineering, production, and distribution of medical devices specifically designed for compatibility with magnetic resonance imaging (MRI) environments. The company supplies these specialized products, alongside their related accessories and support services, to both U.S. and international markets. Key offerings include the MRidium MRI-compatible intravenous (IV) infusion pump system, which comes with disposable tubing sets, and an MRI-compatible patient vital signs monitoring system. Furthermore, IRADIMED provides a range of complementary items such as non-magnetic IV poles, wireless remote displays/controls, side car pump modules, dose error reduction systems, and SpO2 monitoring solutions with sensors. Their clientele primarily consists of hospitals, acute care facilities, and outpatient imaging centers. Sales are conducted via direct field representatives, regional sales directors, clinical support specialists, and independent distributors. Founded in 1992, IRADIMED CORPORATION is headquartered in Winter Springs, Florida.

        CEO
        Roger E. Susi
        Employees
        166
        Beta
        0.91

        Explore

        Frequently asked questions

        What is the intrinsic value of IRadimed Corporation (IRMD)?

        IRadimed Corporation (IRMD) is currently overvalued based on the InvestorsCraft IC model — IC value is 20–50% below the price. The exact intrinsic value is available to Pro subscribers. How the IC value is calculated.

        Is IRMD undervalued?

        IRMD trades at a price of $81.02 (Nov 21, 2026): overvalued — IC value is 20–50% below the price.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.